ID   SHIP2_HUMAN             Reviewed;        1258 AA.
AC   O15357; B2RTX5; Q13577; Q13578;
DT   11-SEP-2007, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 2.
DT   10-MAY-2017, entry version 135.
DE   RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2;
DE            EC=3.1.3.86;
DE   AltName: Full=Inositol polyphosphate phosphatase-like protein 1;
DE            Short=INPPL-1;
DE   AltName: Full=Protein 51C;
DE   AltName: Full=SH2 domain-containing inositol 5'-phosphatase 2;
DE            Short=SH2 domain-containing inositol phosphatase 2;
DE            Short=SHIP-2;
GN   Name=INPPL1; Synonyms=SHIP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=8530088; DOI=10.1006/geno.1995.1247;
RA   Hejna J.A., Saito H., Merkens L.S., Tittle T.V., Jakobs P.M.,
RA   Whitney M.A., Grompe M., Friedberg A.S., Moses R.E.;
RT   "Cloning and characterization of a human cDNA (INPPL1) sharing
RT   homology with inositol polyphosphate phosphatases.";
RL   Genomics 29:285-287(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANT GLY-1114.
RC   TISSUE=Hippocampus;
RX   PubMed=9367831; DOI=10.1006/bbrc.1997.7538;
RA   Pesesse X., Deleu S., De Smedt F., Drayer L., Erneux C.;
RT   "Identification of a second SH2-domain-containing protein closely
RT   related to the phosphatidylinositol polyphosphate 5-phosphatase
RT   SHIP.";
RL   Biochem. Biophys. Res. Commun. 239:697-700(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLY-1114.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   GLY-1114.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, ENZYME ACTIVITY, TISSUE SPECIFICITY, PHOSPHORYLATION, AND
RP   INTERACTION WITH SHC1.
RX   PubMed=9660833; DOI=10.1074/jbc.273.29.18605;
RA   Habib T., Hejna J.A., Moses R.E., Decker S.J.;
RT   "Growth factors and insulin stimulate tyrosine phosphorylation of the
RT   51C/SHIP2 protein.";
RL   J. Biol. Chem. 273:18605-18609(1998).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY, ENZYME ACTIVITY, PHOSPHORYLATION,
RP   AND INTERACTION WITH SHC1 AND ABL1.
RX   PubMed=10194451;
RA   Wisniewski D., Strife A., Swendeman S., Erdjument-Bromage H.,
RA   Geromanos S., Kavanaugh W.M., Tempst P., Clarkson B.;
RT   "A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-
RT   phosphatase (SHIP2) is constitutively tyrosine phosphorylated and
RT   associated with src homologous and collagen gene (SHC) in chronic
RT   myelogenous leukemia progenitor cells.";
RL   Blood 93:2707-2720(1999).
RN   [8]
RP   INTERACTION WITH FCGR2B.
RX   PubMed=11016922; DOI=10.1074/jbc.M003518200;
RA   Bruhns P., Vely F., Malbec O., Fridman W.H., Vivier E., Daeeron M.;
RT   "Molecular basis of the recruitment of the SH2 domain-containing
RT   inositol 5-phosphatases SHIP1 and SHIP2 by fcgamma RIIB.";
RL   J. Biol. Chem. 275:37357-37364(2000).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH EGFR AND SHC1, AND
RP   PHOSPHORYLATION AT TYR-986.
RX   PubMed=11349134; DOI=10.1074/jbc.M103537200;
RA   Pesesse X., Dewaste V., De Smedt F., Laffargue M., Giuriato S.,
RA   Moreau C., Payrastre B., Erneux C.;
RT   "The Src homology 2 domain containing inositol 5-phosphatase SHIP2 is
RT   recruited to the epidermal growth factor (EGF) receptor and
RT   dephosphorylates phosphatidylinositol 3,4,5-trisphosphate in EGF-
RT   stimulated COS-7 cells.";
RL   J. Biol. Chem. 276:28348-28355(2001).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH FLNA AND FLNB.
RX   PubMed=11739414; DOI=10.1083/jcb.200104005;
RA   Dyson J.M., O'Malley C.J., Becanovic J., Munday A.D., Berndt M.C.,
RA   Coghill I.D., Nandurkar H.H., Ooms L.M., Mitchell C.A.;
RT   "The SH2-containing inositol polyphosphate 5-phosphatase, SHIP-2,
RT   binds filamin and regulates submembraneous actin.";
RL   J. Cell Biol. 155:1065-1079(2001).
RN   [11]
RP   PHOSPHORYLATION, INTERACTION WITH BCAR1, AND MUTAGENESIS OF ARG-47.
RX   PubMed=11158326; DOI=10.1128/MCB.21.4.1416-1428.2001;
RA   Prasad N., Topping R.S., Decker S.J.;
RT   "SH2-containing inositol 5'-phosphatase SHIP2 associates with the
RT   p130(Cas) adapter protein and regulates cellular adhesion and
RT   spreading.";
RL   Mol. Cell. Biol. 21:1416-1428(2001).
RN   [12]
RP   PHOSPHORYLATION AT TYR-1162.
RX   PubMed=11687594; DOI=10.1074/jbc.M109992200;
RA   Steen H., Kuster B., Fernandez M., Pandey A., Mann M.;
RT   "Tyrosine phosphorylation mapping of the epidermal growth factor
RT   receptor signaling pathway.";
RL   J. Biol. Chem. 277:1031-1039(2002).
RN   [13]
RP   FUNCTION, PHOSPHORYLATION AT TYR-986, AND MUTAGENESIS OF
RP   986-TYR-TYR-987.
RX   PubMed=12235291; DOI=10.1242/jcs.00070;
RA   Prasad N., Topping R.S., Decker S.J.;
RT   "Src family tyrosine kinases regulate adhesion-dependent tyrosine
RT   phosphorylation of 5'-inositol phosphatase SHIP2 during cell
RT   attachment and spreading on collagen I.";
RL   J. Cell Sci. 115:3807-3815(2002).
RN   [14]
RP   INTERACTION WITH CBL AND SORBS1.
RX   PubMed=12504111; DOI=10.1016/S0006-291X(02)02894-2;
RA   Vandenbroere I., Paternotte N., Dumont J.E., Erneux C., Pirson I.;
RT   "The c-Cbl-associated protein and c-Cbl are two new partners of the
RT   SH2-containing inositol polyphosphate 5-phosphatase SHIP2.";
RL   Biochem. Biophys. Res. Commun. 300:494-500(2003).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION
RP   WITH ACTIN; FILAMIN AND GPIB.
RX   PubMed=12676785; DOI=10.1182/blood-2002-09-2897;
RA   Dyson J.M., Munday A.D., Kong A.M., Huysmans R.D., Matzaris M.,
RA   Layton M.J., Nandurkar H.H., Berndt M.C., Mitchell C.A.;
RT   "SHIP-2 forms a tetrameric complex with filamin, actin, and GPIb-IX-V:
RT   localization of SHIP-2 to the activated platelet actin cytoskeleton.";
RL   Blood 102:940-948(2003).
RN   [16]
RP   FUNCTION, TISSUE SPECIFICITY, INDUCTION, PHOSPHORYLATION, INTERACTION
RP   WITH FCGR2A, AND MUTAGENESIS OF ARG-47 AND ASP-607.
RX   PubMed=12690104; DOI=10.1074/jbc.M302907200;
RA   Pengal R.A., Ganesan L.P., Fang H., Marsh C.B., Anderson C.L.,
RA   Tridandapani S.;
RT   "SHIP-2 inositol phosphatase is inducibly expressed in human monocytes
RT   and serves to regulate Fcgamma receptor-mediated signaling.";
RL   J. Biol. Chem. 278:22657-22663(2003).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1135, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [19]
RP   ENZYME REGULATION.
RX   PubMed=16824732; DOI=10.1016/j.cellsig.2006.05.010;
RA   Vandeput F., Backers K., Villeret V., Pesesse X., Erneux C.;
RT   "The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5-
RT   trisphosphate 5-phosphatase activity.";
RL   Cell. Signal. 18:2193-2199(2006).
RN   [20]
RP   INTERACTION WITH SORBS3.
RX   PubMed=16302969; DOI=10.1111/j.1742-4658.2005.04996.x;
RA   Paternotte N., Zhang J., Vandenbroere I., Backers K., Blero D.,
RA   Kioka N., Vanderwinden J.-M., Pirson I., Erneux C.;
RT   "SHIP2 interaction with the cytoskeletal protein Vinexin.";
RL   FEBS J. 272:6052-6066(2005).
RN   [21]
RP   FUNCTION.
RX   PubMed=15668240; DOI=10.1074/jbc.M410289200;
RA   Prasad N.K., Decker S.J.;
RT   "SH2-containing 5'-inositol phosphatase, SHIP2, regulates cytoskeleton
RT   organization and ligand-dependent down-regulation of the epidermal
RT   growth factor receptor.";
RL   J. Biol. Chem. 280:13129-13136(2005).
RN   [22]
RP   INTERACTION WITH MET.
RX   PubMed=15735664; DOI=10.1038/sj.onc.1208558;
RA   Koch A., Mancini A., El Bounkari O., Tamura T.;
RT   "The SH2-domain-containing inositol 5-phosphatase (SHIP)-2 binds to c-
RT   Met directly via tyrosine residue 1356 and involves hepatocyte growth
RT   factor (HGF)-induced lamellipodium formation, cell scattering and cell
RT   spreading.";
RL   Oncogene 24:3436-3447(2005).
RN   [23]
RP   INTERACTION WITH CENTD3.
RX   PubMed=17314030; DOI=10.1016/j.cellsig.2006.12.015;
RA   Raaijmakers J.H., Deneubourg L., Rehmann H., de Koning J., Zhang Z.,
RA   Krugmann S., Erneux C., Bos J.L.;
RT   "The PI3K effector Arap3 interacts with the PI(3,4,5)P3 phosphatase
RT   SHIP2 in a SAM domain-dependent manner.";
RL   Cell. Signal. 19:1249-1257(2007).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH EPHA2.
RX   PubMed=17135240; DOI=10.1074/jbc.M608509200;
RA   Zhuang G., Hunter S., Hwang Y., Chen J.;
RT   "Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase
RT   via phosphatidylinositol 3-Kinase-dependent Rac1 activation.";
RL   J. Biol. Chem. 282:2683-2694(2007).
RN   [25]
RP   PHOSPHORYLATION AT THR-958, AND MUTAGENESIS OF THR-958.
RX   PubMed=17219406; DOI=10.1002/jcp.20965;
RA   Artemenko Y., Gagnon A., Ibrahim S., Sorisky A.;
RT   "Regulation of PDGF-stimulated SHIP2 tyrosine phosphorylation and
RT   association with Shc in 3T3-L1 preadipocytes.";
RL   J. Cell. Physiol. 211:598-607(2007).
RN   [26]
RP   INVOLVEMENT IN NIDDM.
RX   PubMed=12086927; DOI=10.2337/diabetes.51.7.2012;
RA   Marion E., Kaisaki P.J., Pouillon V., Gueydan C., Levy J.C.,
RA   Bodson A., Krzentowski G., Daubresse J.-C., Mockel J., Behrends J.,
RA   Servais G., Szpirer C., Kruys V., Gauguier D., Schurmans S.;
RT   "The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate
RT   for type 2 diabetes in rat and man.";
RL   Diabetes 51:2012-2017(2002).
RN   [27]
RP   INVOLVEMENT IN METABOLIC SYNDROME.
RX   PubMed=15220217; DOI=10.2337/diabetes.53.7.1900;
RA   Kaisaki P.J., Delepine M., Woon P.Y., Sebag-Montefiore L.,
RA   Wilder S.P., Menzel S., Vionnet N., Marion E., Riveline J.-P.,
RA   Charpentier G., Schurmans S., Levy J.C., Lathrop M., Farrall M.,
RA   Gauguier D.;
RT   "Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase
RT   (INPPL1, SHIP2) are associated with physiological abnormalities of the
RT   metabolic syndrome.";
RL   Diabetes 53:1900-1904(2004).
RN   [28]
RP   INVOLVEMENT IN NIDDM, AND VARIANTS ILE-632; MET-721; SER-982 AND
RP   GLY-1083.
RX   PubMed=15687335; DOI=10.1210/jc.2004-1724;
RA   Kagawa S., Sasaoka T., Yaguchi S., Ishihara H., Tsuneki H.,
RA   Murakami S., Fukui K., Wada T., Kobayashi S., Kimura I., Kobayashi M.;
RT   "Impact of SRC homology 2-containing inositol 5'-phosphatase 2 gene
RT   polymorphisms detected in a Japanese population on insulin
RT   signaling.";
RL   J. Clin. Endocrinol. Metab. 90:2911-2919(2005).
RN   [29]
RP   INVOLVEMENT IN METABOLIC SYNDROME.
RX   PubMed=17557929; DOI=10.1136/jmg.2007.049718;
RA   Braga Marcano A.C., Burke B., Gungadoo J., Wallace C., Kaisaki P.J.,
RA   Woon P.Y., Farrall M., Clayton D., Brown M., Dominiczak A.,
RA   Connell J.M., Webster J., Lathrop M., Caulfield M., Samani N.,
RA   Gauguier D., Munroe P.B.;
RT   "Genetic association analysis of inositol polyphosphate phosphatase-
RT   like 1 (INPPL1, SHIP2) variants with essential hypertension.";
RL   J. Med. Genet. 44:603-605(2007).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-165 AND SER-241, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [34]
RP   FUNCTION, INTERACTION WITH SH3YL1, AND MUTAGENESIS OF 140-PRO-LEU-141.
RX   PubMed=21624956; DOI=10.1083/jcb.201012161;
RA   Hasegawa J., Tokuda E., Tenno T., Tsujita K., Sawai H., Hiroaki H.,
RA   Takenawa T., Itoh T.;
RT   "SH3YL1 regulates dorsal ruffle formation by a novel phosphoinositide-
RT   binding domain.";
RL   J. Cell Biol. 193:901-916(2011).
RN   [35]
RP   FUNCTION, AND VARIANTS OPSMD TRP-401; SER-659; CYS-688 AND ILE-722.
RX   PubMed=23273569; DOI=10.1016/j.ajhg.2012.11.015;
RA   Huber C., Faqeih E.A., Bartholdi D., Bole-Feysot C., Borochowitz Z.,
RA   Cavalcanti D.P., Frigo A., Nitschke P., Roume J., Santos H.G.,
RA   Shalev S.A., Superti-Furga A., Delezoide A.L., Le Merrer M.,
RA   Munnich A., Cormier-Daire V.;
RT   "Exome sequencing identifies INPPL1 mutations as a cause of
RT   opsismodysplasia.";
RL   Am. J. Hum. Genet. 92:144-149(2013).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-132; SER-352; TYR-886;
RP   SER-890; THR-958; SER-1131; TYR-1135; TYR-1162 AND SER-1257, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: Phosphatidylinositol (PtdIns) phosphatase that
CC       specifically hydrolyzes the 5-phosphate of phosphatidylinositol-
CC       3,4,5-trisphosphate (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2,
CC       thereby negatively regulating the PI3K (phosphoinositide 3-kinase)
CC       pathways. Plays a central role in regulation of PI3K-dependent
CC       insulin signaling, although the precise molecular mechanisms and
CC       signaling pathways remain unclear. While overexpression reduces
CC       both insulin-stimulated MAP kinase and Akt activation, its absence
CC       does not affect insulin signaling or GLUT4 trafficking. Confers
CC       resistance to dietary obesity. May act by regulating AKT2, but not
CC       AKT1, phosphorylation at the plasma membrane. Part of a signaling
CC       pathway that regulates actin cytoskeleton remodeling. Required for
CC       the maintenance and dynamic remodeling of actin structures as well
CC       as in endocytosis, having a major impact on ligand-induced EGFR
CC       internalization and degradation. Participates in regulation of
CC       cortical and submembraneous actin by hydrolyzing PtdIns(3,4,5)P3
CC       thereby regulating membrane ruffling (PubMed:21624956). Regulates
CC       cell adhesion and cell spreading. Required for HGF-mediated
CC       lamellipodium formation, cell scattering and spreading. Acts as a
CC       negative regulator of EPHA2 receptor endocytosis by inhibiting via
CC       PI3K-dependent Rac1 activation. Acts as a regulator of
CC       neuritogenesis by regulating PtdIns(3,4,5)P3 level and is required
CC       to form an initial protrusive pattern, and later, maintain proper
CC       neurite outgrowth. Acts as a negative regulator of the FC-gamma-
CC       RIIA receptor (FCGR2A). Mediates signaling from the FC-gamma-RIIB
CC       receptor (FCGR2B), playing a central role in terminating signal
CC       transduction from activating immune/hematopoietic cell receptor
CC       systems. Involved in EGF signaling pathway. Upon stimulation by
CC       EGF, it is recruited by EGFR and dephosphorylates PtdIns(3,4,5)P3.
CC       Plays a negative role in regulating the PI3K-PKB pathway, possibly
CC       by inhibiting PKB activity. Down-regulates Fc-gamma-R-mediated
CC       phagocytosis in macrophages independently of INPP5D/SHIP1. In
CC       macrophages, down-regulates NF-kappa-B-dependent gene
CC       transcription by regulating macrophage colony-stimulating factor
CC       (M-CSF)-induced signaling. May also hydrolyze PtdIns(1,3,4,5)P4,
CC       and could thus affect the levels of the higher inositol
CC       polyphosphates like InsP6. Involved in endochondral ossification.
CC       {ECO:0000269|PubMed:11349134, ECO:0000269|PubMed:11739414,
CC       ECO:0000269|PubMed:12235291, ECO:0000269|PubMed:12676785,
CC       ECO:0000269|PubMed:12690104, ECO:0000269|PubMed:15668240,
CC       ECO:0000269|PubMed:17135240, ECO:0000269|PubMed:21624956,
CC       ECO:0000269|PubMed:23273569, ECO:0000269|PubMed:9660833}.
CC   -!- CATALYTIC ACTIVITY: 1-phosphatidyl-1D-myo-inositol 3,4,5-
CC       triphosphate + H(2)O = 1-phosphatidyl-1D-myo-inositol 3,4-
CC       diphosphate + phosphate. {ECO:0000269|PubMed:10194451,
CC       ECO:0000269|PubMed:21624956, ECO:0000269|PubMed:9660833}.
CC   -!- ENZYME REGULATION: Activated upon translocation to the sites of
CC       synthesis of PtdIns(3,4,5)P3 in the membrane. Enzymatic activity
CC       is enhanced in the presence of phosphatidylserine.
CC       {ECO:0000269|PubMed:16824732}.
CC   -!- SUBUNIT: Interacts with tyrosine phosphorylated form of SHC1,
CC       Interacts with EGFR. Upon stimulation by the EGF signaling
CC       pathway, it forms a complex with SHC1 and EGFR. Interacts with
CC       cytoskeletal protein SORBS3/vinexin, promoting its localization to
CC       the periphery of cells. Forms a complex with filamin (FLNA or
CC       FLNB), actin, GPIb (GP1BA or GP1BB) that regulates cortical and
CC       submembraneous actin. Interacts with c-Met/MET, when c-Met/MET is
CC       phosphorylated on 'Tyr-1356'. Interacts with p130Cas/BCAR1.
CC       Interacts with CENTD3/ARAP3 via its SAM domain. Interacts with c-
CC       Cbl/CBL and CAP/SORBS1. Interacts with activated EPHA2 receptor.
CC       Interacts with receptors FCGR2A and FCGR2B. Interacts with
CC       tyrosine kinases ABL1 and TEC. Interacts with CSF1R. Interacts
CC       (via N-terminus) with SH3YL1 (via SH3 domain) (PubMed:21624956).
CC       {ECO:0000269|PubMed:10194451, ECO:0000269|PubMed:11016922,
CC       ECO:0000269|PubMed:11158326, ECO:0000269|PubMed:11349134,
CC       ECO:0000269|PubMed:11739414, ECO:0000269|PubMed:12504111,
CC       ECO:0000269|PubMed:12676785, ECO:0000269|PubMed:12690104,
CC       ECO:0000269|PubMed:15735664, ECO:0000269|PubMed:16302969,
CC       ECO:0000269|PubMed:17135240, ECO:0000269|PubMed:17314030,
CC       ECO:0000269|PubMed:9660833}.
CC   -!- INTERACTION:
CC       P10275:AR; NbExp=3; IntAct=EBI-1384248, EBI-608057;
CC       P56945:BCAR1; NbExp=2; IntAct=EBI-1384248, EBI-702093;
CC       Q13480:GAB1; NbExp=2; IntAct=EBI-1384248, EBI-517684;
CC       A0A061I5T4:H671_4g13114 (xeno); NbExp=2; IntAct=EBI-1384248, EBI-2504267;
CC       Q8IV36:HID1; NbExp=2; IntAct=EBI-1384248, EBI-743438;
CC       Q15811-2:ITSN1; NbExp=9; IntAct=EBI-1384248, EBI-8052395;
CC       P08581:MET; NbExp=2; IntAct=EBI-1384248, EBI-1039152;
CC       Q9BX66:SORBS1; NbExp=5; IntAct=EBI-1384248, EBI-433642;
CC       O60504-1:SORBS3; NbExp=2; IntAct=EBI-1384248, EBI-1222953;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cytoplasm, cytoskeleton.
CC       Membrane; Peripheral membrane protein. Cell projection,
CC       filopodium. Cell projection, lamellipodium. Note=Translocates to
CC       membrane ruffles when activated, translocation is probably due to
CC       different mechanisms depending on the stimulus and cell type.
CC       Partly translocated via its SH2 domain which mediates interaction
CC       with tyrosine phosphorylated receptors such as the FC-gamma-RIIB
CC       receptor (FCGR2B). Tyrosine phosphorylation may also participate
CC       in membrane localization. Insulin specifically stimulates its
CC       redistribution from the cytosol to the plasma membrane. Recruited
CC       to the membrane following M-CSF stimulation. In activated
CC       spreading platelets, localizes with actin at filopodia,
CC       lamellipodia and the central actin ring.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O15357-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15357-2; Sequence=VSP_027985;
CC   -!- TISSUE SPECIFICITY: Widely expressed, most prominently in skeletal
CC       muscle, heart and brain. Present in platelets. Expressed in
CC       transformed myeloid cells and in primary macrophages, but not in
CC       peripheral blood monocytes. {ECO:0000269|PubMed:12676785,
CC       ECO:0000269|PubMed:12690104, ECO:0000269|PubMed:8530088,
CC       ECO:0000269|PubMed:9367831, ECO:0000269|PubMed:9660833}.
CC   -!- INDUCTION: By bacterial lipopolysaccharides (LPS).
CC       {ECO:0000269|PubMed:12690104}.
CC   -!- DOMAIN: The SH2 domain interacts with tyrosine phosphorylated
CC       forms of proteins such as SHC1 or FCGR2A. It also mediates the
CC       interaction with p130Cas/BCAR1.
CC   -!- DOMAIN: The NPXY sequence motif found in many tyrosine-
CC       phosphorylated proteins is required for the specific binding of
CC       the PID domain. {ECO:0000250}.
CC   -!- PTM: Tyrosine phosphorylated by the members of the SRC family
CC       after exposure to a diverse array of extracellular stimuli such as
CC       insulin, growth factors such as EGF or PDGF, chemokines, integrin
CC       ligands and hypertonic and oxidative stress. May be phosphorylated
CC       upon IgG receptor FCGR2B-binding. Phosphorylated at Tyr-986
CC       following cell attachment and spreading. Phosphorylated at Tyr-
CC       1162 following EGF signaling pathway stimulation. Phosphorylated
CC       at Thr-958 in response to PDGF. {ECO:0000269|PubMed:10194451,
CC       ECO:0000269|PubMed:11158326, ECO:0000269|PubMed:11349134,
CC       ECO:0000269|PubMed:11687594, ECO:0000269|PubMed:12235291,
CC       ECO:0000269|PubMed:12690104, ECO:0000269|PubMed:17219406,
CC       ECO:0000269|PubMed:9660833}.
CC   -!- DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM)
CC       [MIM:125853]: A multifactorial disorder of glucose homeostasis
CC       caused by a lack of sensitivity to the body's own insulin.
CC       Affected individuals usually have an obese body habitus and
CC       manifestations of a metabolic syndrome characterized by diabetes,
CC       insulin resistance, hypertension and hypertriglyceridemia. The
CC       disease results in long-term complications that affect the eyes,
CC       kidneys, nerves, and blood vessels. {ECO:0000269|PubMed:12086927,
CC       ECO:0000269|PubMed:15687335}. Note=Disease susceptibility may be
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=Genetic variations in INPPL1 may be a cause of
CC       susceptibility to metabolic syndrome. Metabolic syndrome is
CC       characterized by diabetes, insulin resistance, hypertension, and
CC       hypertriglyceridemia is absent. {ECO:0000269|PubMed:15220217,
CC       ECO:0000269|PubMed:17557929}.
CC   -!- DISEASE: Opsismodysplasia (OPSMD) [MIM:258480]: A rare skeletal
CC       dysplasia involving delayed bone maturation. Clinical signs
CC       observed at birth include short limbs, small hands and feet,
CC       relative macrocephaly with a large anterior fontanel, and
CC       characteristic craniofacial abnormalities including a prominent
CC       brow, depressed nasal bridge, a small anteverted nose, and a
CC       relatively long philtrum. Death secondary to respiratory failure
CC       during the first few years of life has been reported, but there
CC       can be long-term survival. Typical radiographic findings include
CC       shortened long bones with very delayed epiphyseal ossification,
CC       severe platyspondyly, metaphyseal cupping, and characteristic
CC       abnormalities of the metacarpals and phalanges.
CC       {ECO:0000269|PubMed:23273569}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Its ability to confer resistance to dietary obesity
CC       suggests that it may serve as a possible therapeutic target in
CC       cases of type 2 diabetes and obesity.
CC   -!- SIMILARITY: Belongs to the inositol 1,4,5-trisphosphate 5-
CC       phosphatase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA50503.1; Type=Frameshift; Positions=1153; Evidence={ECO:0000305};
CC       Sequence=AAA96658.1; Type=Frameshift; Positions=Several; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/INPPL1ID40984ch11q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L24444; AAA50503.1; ALT_FRAME; mRNA.
DR   EMBL; L36818; AAA96658.1; ALT_FRAME; mRNA.
DR   EMBL; Y14385; CAA74743.1; -; mRNA.
DR   EMBL; AP000593; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471076; EAW74855.1; -; Genomic_DNA.
DR   EMBL; BC140853; AAI40854.1; -; mRNA.
DR   CCDS; CCDS8213.1; -. [O15357-1]
DR   PIR; JC5765; JC5765.
DR   RefSeq; NP_001558.3; NM_001567.3. [O15357-1]
DR   RefSeq; XP_011543301.1; XM_011544999.2. [O15357-1]
DR   UniGene; Hs.523875; -.
DR   PDB; 2K4P; NMR; -; A=1194-1258.
DR   PDB; 2KSO; NMR; -; B=1200-1258.
DR   PDB; 2MK2; NMR; -; A=20-117.
DR   PDB; 3NR8; X-ray; 2.80 A; A/B=419-732.
DR   PDB; 4A9C; X-ray; 2.10 A; A/B=419-732.
DR   PDBsum; 2K4P; -.
DR   PDBsum; 2KSO; -.
DR   PDBsum; 2MK2; -.
DR   PDBsum; 3NR8; -.
DR   PDBsum; 4A9C; -.
DR   ProteinModelPortal; O15357; -.
DR   SMR; O15357; -.
DR   BioGrid; 109848; 104.
DR   DIP; DIP-39733N; -.
DR   IntAct; O15357; 26.
DR   MINT; MINT-137208; -.
DR   STRING; 9606.ENSP00000298229; -.
DR   BindingDB; O15357; -.
DR   ChEMBL; CHEMBL2331064; -.
DR   GuidetoPHARMACOLOGY; 1459; -.
DR   SwissLipids; SLP:000000953; -.
DR   DEPOD; O15357; -.
DR   iPTMnet; O15357; -.
DR   PhosphoSitePlus; O15357; -.
DR   BioMuta; INPPL1; -.
DR   EPD; O15357; -.
DR   MaxQB; O15357; -.
DR   PaxDb; O15357; -.
DR   PeptideAtlas; O15357; -.
DR   PRIDE; O15357; -.
DR   Ensembl; ENST00000298229; ENSP00000298229; ENSG00000165458. [O15357-1]
DR   Ensembl; ENST00000538751; ENSP00000444619; ENSG00000165458. [O15357-2]
DR   GeneID; 3636; -.
DR   KEGG; hsa:3636; -.
DR   UCSC; uc001osf.4; human. [O15357-1]
DR   CTD; 3636; -.
DR   DisGeNET; 3636; -.
DR   GeneCards; INPPL1; -.
DR   H-InvDB; HIX0201720; -.
DR   HGNC; HGNC:6080; INPPL1.
DR   HPA; HPA037601; -.
DR   MalaCards; INPPL1; -.
DR   MIM; 125853; phenotype.
DR   MIM; 258480; phenotype.
DR   MIM; 600829; gene.
DR   neXtProt; NX_O15357; -.
DR   OpenTargets; ENSG00000165458; -.
DR   Orphanet; 2746; Opsismodysplasia.
DR   PharmGKB; PA29888; -.
DR   eggNOG; KOG0565; Eukaryota.
DR   eggNOG; KOG4384; Eukaryota.
DR   eggNOG; COG5411; LUCA.
DR   GeneTree; ENSGT00760000119075; -.
DR   HOGENOM; HOG000004836; -.
DR   HOVERGEN; HBG106726; -.
DR   InParanoid; O15357; -.
DR   KO; K15909; -.
DR   OMA; TQRKDFI; -.
DR   OrthoDB; EOG091G00P6; -.
DR   PhylomeDB; O15357; -.
DR   TreeFam; TF323475; -.
DR   BioCyc; MetaCyc:HS09233-MONOMER; -.
DR   BRENDA; 3.1.3.86; 2681.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   SABIO-RK; O15357; -.
DR   SignaLink; O15357; -.
DR   SIGNOR; O15357; -.
DR   ChiTaRS; INPPL1; human.
DR   EvolutionaryTrace; O15357; -.
DR   GeneWiki; INPPL1; -.
DR   GenomeRNAi; 3636; -.
DR   PRO; PR:O15357; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000165458; -.
DR   CleanEx; HS_INPPL1; -.
DR   ExpressionAtlas; O15357; baseline and differential.
DR   Genevisible; O15357; HS.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030175; C:filopodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW.
DR   GO; GO:0052659; F:inositol-1,3,4,5-tetrakisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0034485; F:phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0007015; P:actin filament organization; IMP:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; TAS:UniProtKB.
DR   GO; GO:0001958; P:endochondral ossification; IMP:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IMP:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl.
DR   GO; GO:0002376; P:immune system process; IEA:UniProtKB-KW.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IEA:InterPro.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0097178; P:ruffle assembly; IEA:Ensembl.
DR   Gene3D; 3.30.505.10; -; 1.
DR   Gene3D; 3.60.10.10; -; 1.
DR   InterPro; IPR005135; Endo/exonuclease/phosphatase.
DR   InterPro; IPR000300; IPPc.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR000980; SH2.
DR   Pfam; PF03372; Exo_endo_phos; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00128; IPPc; 1.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00252; SH2; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56219; SSF56219; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Actin-binding; Alternative splicing; Cell adhesion;
KW   Cell projection; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Diabetes mellitus; Disease mutation; Hydrolase; Immunity; Membrane;
KW   Phosphoprotein; Polymorphism; Reference proteome; SH2 domain;
KW   SH3-binding.
FT   CHAIN         1   1258       Phosphatidylinositol 3,4,5-trisphosphate
FT                                5-phosphatase 2.
FT                                /FTId=PRO_0000302870.
FT   DOMAIN       21    117       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN     1196   1258       SAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00184}.
FT   MOTIF       944    949       SH3-binding.
FT   MOTIF       983    986       NPXY motif.
FT   COMPBIAS    935   1105       Pro-rich.
FT   MOD_RES     132    132       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     165    165       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     241    241       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     352    352       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     886    886       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     890    890       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     958    958       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:17219406}.
FT   MOD_RES     986    986       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:11349134,
FT                                ECO:0000269|PubMed:12235291}.
FT   MOD_RES    1131   1131       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1135   1135       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1162   1162       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:11687594}.
FT   MOD_RES    1257   1257       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1    242       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8530088}.
FT                                /FTId=VSP_027985.
FT   VARIANT     401    401       R -> W (in OPSMD; dbSNP:rs397514511).
FT                                {ECO:0000269|PubMed:23273569}.
FT                                /FTId=VAR_069586.
FT   VARIANT     632    632       L -> I (associated with susceptibility to
FT                                NIDDM; dbSNP:rs61749195).
FT                                {ECO:0000269|PubMed:15687335}.
FT                                /FTId=VAR_034980.
FT   VARIANT     659    659       P -> S (in OPSMD; dbSNP:rs397514510).
FT                                {ECO:0000269|PubMed:23273569}.
FT                                /FTId=VAR_069587.
FT   VARIANT     688    688       W -> C (in OPSMD).
FT                                {ECO:0000269|PubMed:23273569}.
FT                                /FTId=VAR_069588.
FT   VARIANT     721    721       V -> M (in dbSNP:rs116848359).
FT                                {ECO:0000269|PubMed:15687335}.
FT                                /FTId=VAR_034981.
FT   VARIANT     722    722       F -> I (in OPSMD; dbSNP:rs397514512).
FT                                {ECO:0000269|PubMed:23273569}.
FT                                /FTId=VAR_069589.
FT   VARIANT     982    982       N -> S (associated with susceptibility to
FT                                NIDDM; dbSNP:rs70940821).
FT                                {ECO:0000269|PubMed:15687335}.
FT                                /FTId=VAR_034982.
FT   VARIANT    1083   1083       A -> G (in dbSNP:rs11548491).
FT                                {ECO:0000269|PubMed:15687335}.
FT                                /FTId=VAR_034983.
FT   VARIANT    1114   1114       A -> G (in dbSNP:rs1049472).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:9367831,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_034984.
FT   MUTAGEN      47     47       R->G: Abolishes interaction with
FT                                p130Cas/BCAR1 and its ability to induce
FT                                increased adhesion. Abolishes
FT                                phosphorylation upon FCGR2A clustering.
FT                                {ECO:0000269|PubMed:11158326,
FT                                ECO:0000269|PubMed:12690104}.
FT   MUTAGEN     140    141       PL->AA: Abolishes interaction with
FT                                SH3YL1. {ECO:0000269|PubMed:21624956}.
FT   MUTAGEN     607    607       D->A: Abolishes enzyme activity but not
FT                                phosphorylation upon FCGR2A clustering.
FT                                {ECO:0000269|PubMed:12690104}.
FT   MUTAGEN     958    958       T->A: Reduces PDGF-stimulated tyrosine
FT                                phosphorylation and association with
FT                                SHC1. {ECO:0000269|PubMed:17219406}.
FT   MUTAGEN     986    987       YY->FF: Inducer a strong reduction of
FT                                phosphorylation upon re-plating on
FT                                collagen I.
FT                                {ECO:0000269|PubMed:12235291}.
FT   CONFLICT    307    307       I -> M (in Ref. 1; AAA96658).
FT                                {ECO:0000305}.
FT   CONFLICT   1142   1142       R -> A (in Ref. 1; AAA50503/AAA96658).
FT                                {ECO:0000305}.
FT   STRAND       21     23       {ECO:0000244|PDB:2MK2}.
FT   HELIX        28     38       {ECO:0000244|PDB:2MK2}.
FT   STRAND       41     48       {ECO:0000244|PDB:2MK2}.
FT   STRAND       56     61       {ECO:0000244|PDB:2MK2}.
FT   STRAND       66     72       {ECO:0000244|PDB:2MK2}.
FT   STRAND       75     77       {ECO:0000244|PDB:2MK2}.
FT   STRAND       79     81       {ECO:0000244|PDB:2MK2}.
FT   STRAND       85     87       {ECO:0000244|PDB:2MK2}.
FT   STRAND       91     94       {ECO:0000244|PDB:2MK2}.
FT   HELIX        95    102       {ECO:0000244|PDB:2MK2}.
FT   STRAND      423    432       {ECO:0000244|PDB:4A9C}.
FT   HELIX       443    446       {ECO:0000244|PDB:4A9C}.
FT   STRAND      450    453       {ECO:0000244|PDB:4A9C}.
FT   HELIX       459    461       {ECO:0000244|PDB:4A9C}.
FT   STRAND      465    473       {ECO:0000244|PDB:4A9C}.
FT   HELIX       478    493       {ECO:0000244|PDB:4A9C}.
FT   STRAND      498    505       {ECO:0000244|PDB:4A9C}.
FT   STRAND      508    514       {ECO:0000244|PDB:4A9C}.
FT   HELIX       516    521       {ECO:0000244|PDB:4A9C}.
FT   STRAND      522    532       {ECO:0000244|PDB:4A9C}.
FT   STRAND      541    550       {ECO:0000244|PDB:4A9C}.
FT   STRAND      553    561       {ECO:0000244|PDB:4A9C}.
FT   HELIX       569    582       {ECO:0000244|PDB:4A9C}.
FT   STRAND      586    588       {ECO:0000244|PDB:3NR8}.
FT   TURN        591    593       {ECO:0000244|PDB:3NR8}.
FT   TURN        595    598       {ECO:0000244|PDB:4A9C}.
FT   STRAND      599    607       {ECO:0000244|PDB:4A9C}.
FT   STRAND      612    614       {ECO:0000244|PDB:4A9C}.
FT   HELIX       616    624       {ECO:0000244|PDB:4A9C}.
FT   HELIX       629    632       {ECO:0000244|PDB:4A9C}.
FT   HELIX       636    642       {ECO:0000244|PDB:4A9C}.
FT   STRAND      645    647       {ECO:0000244|PDB:4A9C}.
FT   STRAND      675    677       {ECO:0000244|PDB:4A9C}.
FT   STRAND      680    682       {ECO:0000244|PDB:4A9C}.
FT   STRAND      690    696       {ECO:0000244|PDB:4A9C}.
FT   STRAND      702    709       {ECO:0000244|PDB:4A9C}.
FT   STRAND      715    718       {ECO:0000244|PDB:4A9C}.
FT   STRAND      721    728       {ECO:0000244|PDB:4A9C}.
FT   HELIX      1202   1206       {ECO:0000244|PDB:2K4P}.
FT   TURN       1207   1209       {ECO:0000244|PDB:2K4P}.
FT   HELIX      1211   1213       {ECO:0000244|PDB:2K4P}.
FT   HELIX      1214   1218       {ECO:0000244|PDB:2K4P}.
FT   TURN       1219   1221       {ECO:0000244|PDB:2K4P}.
FT   HELIX      1225   1228       {ECO:0000244|PDB:2K4P}.
FT   HELIX      1233   1238       {ECO:0000244|PDB:2K4P}.
FT   HELIX      1244   1256       {ECO:0000244|PDB:2K4P}.
SQ   SEQUENCE   1258 AA;  138599 MW;  D76B5AA8ACDE8CBA CRC64;
     MASACGAPGP GGALGSQAPS WYHRDLSRAA AEELLARAGR DGSFLVRDSE SVAGAFALCV
     LYQKHVHTYR ILPDGEDFLA VQTSQGVPVR RFQTLGELIG LYAQPNQGLV CALLLPVEGE
     REPDPPDDRD ASDGEDEKPP LPPRSGSTSI SAPTGPSSPL PAPETPTAPA AESAPNGLST
     VSHDYLKGSY GLDLEAVRGG ASHLPHLTRT LATSCRRLHS EVDKVLSGLE ILSKVFDQQS
     SPMVTRLLQQ QNLPQTGEQE LESLVLKLSV LKDFLSGIQK KALKALQDMS STAPPAPQPS
     TRKAKTIPVQ AFEVKLDVTL GDLTKIGKSQ KFTLSVDVEG GRLVLLRRQR DSQEDWTTFT
     HDRIRQLIKS QRVQNKLGVV FEKEKDRTQR KDFIFVSARK REAFCQLLQL MKNKHSKQDE
     PDMISVFIGT WNMGSVPPPK NVTSWFTSKG LGKTLDEVTV TIPHDIYVFG TQENSVGDRE
     WLDLLRGGLK ELTDLDYRPI AMQSLWNIKV AVLVKPEHEN RISHVSTSSV KTGIANTLGN
     KGAVGVSFMF NGTSFGFVNC HLTSGNEKTA RRNQNYLDIL RLLSLGDRQL NAFDISLRFT
     HLFWFGDLNY RLDMDIQEIL NYISRKEFEP LLRVDQLNLE REKHKVFLRF SEEEISFPPT
     YRYERGSRDT YAWHKQKPTG VRTNVPSWCD RILWKSYPET HIICNSYGCT DDIVTSDHSP
     VFGTFEVGVT SQFISKKGLS KTSDQAYIEF ESIEAIVKTA SRTKFFIEFY STCLEEYKKS
     FENDAQSSDN INFLKVQWSS RQLPTLKPIL ADIEYLQDQH LLLTVKSMDG YESYGECVVA
     LKSMIGSTAQ QFLTFLSHRG EETGNIRGSM KVRVPTERLG TRERLYEWIS IDKDEAGAKS
     KAPSVSRGSQ EPRSGSRKPA FTEASCPLSR LFEEPEKPPP TGRPPAPPRA APREEPLTPR
     LKPEGAPEPE GVAAPPPKNS FNNPAYYVLE GVPHQLLPPE PPSPARAPVP SATKNKVAIT
     VPAPQLGHHR HPRVGEGSSS DEESGGTLPP PDFPPPPLPD SAIFLPPSLD PLPGPVVRGR
     GGAEARGPPP PKAHPRPPLP PGPSPASTFL GEVASGDDRS CSVLQMAKTL SEVDYAPAGP
     ARSALLPGPL ELQPPRGLPS DYGRPLSFPP PRIRESIQED LAEEAPCLQG GRASGLGEAG
     MSAWLRAIGL ERYEEGLVHN GWDDLEFLSD ITEEDLEEAG VQDPAHKRLL LDTLQLSK
//
